FDA gives nod to Saxenda for adoloscents’ obesity treatment
Novo Nordisk has said that the United States Food and Drug Administration (FDA) approved an updated label for Saxenda (liraglutide) injection 3 mg for...
Postpartum depression may continue for 3 years after delivery
A new study has has found that approximately 1 in 4 experienced high levels of depressive symptoms at some point in the three years...
Lupus Research Awards 2023 announced
The Lupus Research Alliance (LRA) announced the recipients of the newest Lupus Innovation Award (LIA) grants.
Collectively, the seven projects led by research teams from the U.S. and Europe explore multiple...
COMMUNITY: A global platform trial for hospitalised patients with Covid-19
Three members of the Covid Research & Development Alliance have announced the first patient enrolled in the Community Trial.
The three members are Amgen Inc,...
Drawbridge Health ties up with University of Cambridge researchers
Drawbridge Health and the Medical Research Council (MRC) Epidemiology Unit, University of Cambridge announced the use of the OneDraw Blood Collection Device for remote...
Biological E gets into war against Covid-19, commences clinical trial of its vaccine candidate
Hyderabad-based pharmaceuticals & Biologics company Biological E. Limited (BE), has said it has initiated a Phase I/II clinical trial of its COVID-19 subunit vaccine...
Covid immunity lasts for many months, says study of healthcare workers
In a relief to healthcare workers who put their lives under risk while treating those with Covid-19, new findings from a study of thousands...
Lilly’s tirzepatide brings down body weight in people with type 2 diabetes
Lilly's Tirzepatide led to superior A1C and body weight reductions from baseline in adults with type 2 diabetes.
This was achieved after 40 weeks of...
Codagenix, Serum Institute of India start first-in-human trial of Covid-19 vaccine
Codagenix, Inc., and the Serum Institute of India Pvt. Ltd. (SIIPL) have announced that a Phase 1 clinical trial of COVI-VAC received regulatory approval...
Ampio says its study on Covid-19 patients proceeding to full open enrollment
Ampio Pharmaceuticals Inc has announced that its AP-014 Phase I inhaled Ampion clinical study in Covid-19 patients is proceeding to full open enrollment after...
